Kyntra Bio (KYNB) Equity Income (2020 - 2025)

Kyntra Bio has disclosed Equity Income across 6 years of filings, most recently posting $1.4 million for Q3 2025.

• In Q3 2025, Equity Income rose 55.9% year-over-year to $1.4 million; the TTM figure through Dec 2025 stood at $3.7 million (down 7.5% YoY), while the FY2025 annual figure was $2.5 million, down 37.5% from the prior year.
• Equity Income came in at $1.4 million for Q3 2025 at Kyntra Bio, down from $1.7 million in the prior quarter.
• In the past five years, Equity Income ranged from a high of $1.7 million in Q2 2025 to a low of -$240000.0 in Q1 2021.
• Average Equity Income over 5 years is $679842.1, with a median of $589000.0 recorded in 2024.
• Year-over-year, Equity Income jumped 2730.77% in 2021 and slipped 26.01% in 2024.
• Over 5 years, Equity Income stood at $343000.0 in 2021, then dropped by 18.37% to $280000.0 in 2022, then surged by 119.64% to $615000.0 in 2023, then jumped by 117.24% to $1.3 million in 2024, then rose by 4.79% to $1.4 million in 2025.
• Per Business Quant data, the three most recent Equity Income figures were $1.4 million in Q3 2025, $1.7 million in Q2 2025, and $600000.0 in Q1 2025.